KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Assets (2016 - 2025)

Historic Return on Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 0.28%.

  • Halozyme Therapeutics' Return on Assets rose 900.0% to 0.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.28%, marking a year-over-year increase of 900.0%. This contributed to the annual value of 0.23% for FY2024, which is 800.0% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Return on Assets stood at 0.28%, which was up 900.0% from 0.26% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Return on Assets high stood at 0.38% for Q1 2022, and its period low was 0.1% during Q1 2023.
  • Moreover, its 5-year median value for Return on Assets was 0.21% (2021), whereas its average is 0.21%.
  • As far as peak fluctuations go, Halozyme Therapeutics' Return on Assets skyrocketed by 3600bps in 2021, and later crashed by -2800bps in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Return on Assets stood at 0.35% in 2021, then plummeted by -69bps to 0.11% in 2022, then surged by 42bps to 0.16% in 2023, then skyrocketed by 37bps to 0.21% in 2024, then surged by 31bps to 0.28% in 2025.
  • Its Return on Assets was 0.28% in Q3 2025, compared to 0.26% in Q2 2025 and 0.23% in Q1 2025.